Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241162 | 1.00 | GCK (0.53) | GCK | |
| SCHEMBL3241168 | 1.00 | GCK (0.53) | GCK | |
| SCHEMBL27685666 | 1.00 | GCK (0.53) | GCK | |
| SCHEMBL2667396 | 0.86 | GCK (0.62) | GCK | |
| SCHEMBL14216763 | 0.86 | GCK (0.52) | GCK | |
| SCHEMBL2513491 | 0.85 | GCK (0.53) | GCK | |
| SCHEMBL2513488 | 0.85 | GCK (0.53) | GCK | |
| SCHEMBL2658840 | 0.84 | GCK (0.61) | GCK | |
| SCHEMBL3232344 | 0.83 | GCK (0.49) | GCK | |
| SCHEMBL3232338 | 0.83 | GCK (0.49) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | claimed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | claimed |
| EP-1789396-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Prosidion Limited (GB) | 2007-05-30 | — | — | EP | claimed |
| WO-2006016194-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | claimed |
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| EP-1789396-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Prosidion Limited (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006016194-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016194-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | GPR119, SLC5A2, SLC5A1 | GCK 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.